Therapeutically, targeting the WISP-1-integrin α5β3-STAT1 pathway offers a promising strategy to reprogram immunosuppressive TAMs, potentiate anti-tumor immunity, and improve the efficacy of immunotherapies in lung cancer and potentially other solid malignancies. Here, STAT1 is linked to neoplasm.